Good afternoon and welcome to Markets Desk, your midday read on what's moving and why.
CVS Health is drawing fresh attention from value investors as the pharmacy and insurance giant shows signs of a genuine operational turnaround. After years of margin pressure and restructuring noise, improving financial results are prompting analysts to flag the stock as meaningfully undervalued relative to peers in the managed care space.
Shifting to the commodity pits, live cattle futures finished Monday sharply higher, with gains ranging from seventy-five cents to three dollars across the board. The catalyst was broader risk appetite — a weekend diplomatic agreement between the United States and Iran lifted equities, and that optimism spilled directly into the livestock complex. Cash trade last week settled in the two hundred fifty-five to two hundred fifty-eight dollar range nationally.
On the regulatory front, Cuprina Holdings saw its shares more than double after its subsidiary received FDA five-ten-k clearance for MEDIFLY Maggots in wound debridement. That approval marks a significant commercial milestone for the biomedical firm, validating a therapy that uses larvae to remove damaged tissue — a centuries-old technique now backed by modern regulatory standing.
That's the tape. Markets Desk, signing off the floor.
